← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,674	-6	-0.4%	$99.9B
2	2 Danaher DHR $158B	1,502	-15	-1%	$76.3B
3	3 Novartis NVS $279B	1,132	-41	-3%	$20.4B
4	4 Illumina ILMN $41B	824	-66	-7%	$36.6B
5	5 Regeneron Pharmaceuticals REGN $80.1B	816	+113	+16%	$36.9B
6	6 Agilent Technologies A $49.1B	716	-36	-5%	$19.4B
7	7 Revvity RVTY $17B	423	-7	-2%	$7.91B
8	8 Charles River Laboratories CRL $14.4B	414	+1	+0.2%	$5.9B
9	9 Sarepta Therapeutics SRPT $1.78B	366	-24	-6%	$7.21B
10	10 Ionis Pharmaceuticals IONS $7.1B	363	-28	-7%	$5.6B
11	11 Alnylam Pharmaceuticals ALNY $30B	331	+15	+5%	$11.8B
12	12 DELISTED CATALENT, INC. CTLT	326	+38	+13%	$8.24B
13	13 Guardant Health GH $21.9B	288	+20	+7%	$5.46B
14	14 Qiagen QGEN $9.41B	260	-37	-12%	$5.98B
15	15 CRISPR Therapeutics CRSP $4.86B	257	+4	+2%	$1.51B
16	16 Azenta AZTA $1.63B	251	-42	-14%	$2.24B
17	17 DELISTED bluebird bio BLUE	247	-27	-10%	$2.7B
18	18 Arrowhead Research ARWR $8.25B	241	-50	-17%	$1.93B
19	19 Bruker BRKR $8.47B	240	-35	-13%	$3.91B
20	20 PTC Therapeutics PTCT $4.98B	203	-3	-1%	$2.87B
21	21 Editas Medicine EDIT $349M	199	-30	-13%	$909M
22	22 DELISTED SANGAMO THERAPEUTICS INC SGMO	190	-3	-2%	$476M
23	23 Myriad Genetics MYGN $397M	189	-38	-17%	$1.06B
24	NVTA 24 DELISTED Invitae Corporation NVTA	180	-10	-5%	$1.41B
25	25 Ultragenyx Pharmaceutical RARE $1.47B	174	+1	+0.6%	$2.67B